Table 2.
Pathological Lesions at Death (in Order From Most Common to Least Common)
| Control | Rapamycin | |
|---|---|---|
| Males | ||
| Lesion type | ||
| Seminal vesicle cysts | 0.91 (31/45) | 0.91 (39/43) |
| Lymphoma | 0.60 (27/45) | 0.56 (24/43) |
| Alveolar/bronchiolar adenoma | 0.40 (18/45) | 0.19 (8/43) |
| Kidney lymphocytic infiltrate | 0.33 (15/45) | 0.26 (11/43) |
| Salivary gland lymphocytic infiltrate | 0.30 (13/44) | 0.17 (7/42) |
| Kidney mineralization | 0.27 (12/45) | 0.26 (11/43) |
| Brain mineralization | 0.24 (11/45) | 0.33 (14/43) |
| Hepatic lymphocytic infiltrate | 0.24 (11/45) | 0.07 (3/43) |
| Subscapular adrenal hyperplasia | 0.21 (9/43) | 0.23 (9/40) |
| Hemangioma | 0.20 (9/45) | 0.05 (2/43) |
| Steatosis | 0.16 (7/45) | 0.12 (5/43) |
| Intestinal amyloid | 0.14 (6/44) | 0.26 (11/43) |
| Cardiac amyloid | 0.13 (6/45) | 0.16 (7/43) |
| Pulmonary lymphocytic infiltrate | 0.11 (5/45) | 0.14 (6/43) |
| Presumptive cause of death | ||
| All neoplasia | 0.62 (28/45) | 0.49 (21/43) |
| Nonneoplasia | 0.24 (11/45) | 0.26 (18/43) |
| Females | ||
| Lesion type | ||
| Lymphoma | 0.88 (36/41) | 0.91 (40/44) |
| Subscapular adrenal hyperplasia | 0.71 (29/41) | 0.73 (32/44) |
| Pituitary adenoma | 0.60 (21/35) | 0.49 (16/33) |
| Endometrial hyperplasia | 0.59 (24/41) | 0.65 (28/43) |
| All ovarian lesions | 0.26 (10/38) | 0.18 (7/39) |
| Thyroid adenoma | 0.24 (9/38) | 0.19 (7/37) |
| Thyroid hyperplasia | 0.21 (8/38) | 0.19 (7/37) |
| Brain mineralization | 0.17 (7/41) | 0.18 (8/44) |
| Kidney mineralization | 0.17 (7/41) | 0.21 (9/44) |
| Presumptive cause of death | ||
| All neoplasia | 0.73 (30/41) | 0.70 (31/44) |
| Nonneoplasia | 0.22 (9/41) | 0.16 (7/44) |